TuHURA Biosciences, Inc./NV (HURA): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 07:50 ET
- Event date
- 2026-11-13
- Accession no.
- 0001193125-26-459311
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
TuHURA reports third quarter 2026 financial results and clinical updates
TuHURA reported third quarter 2026 results, including $1.9 million in cash and cash equivalents at September 30, 2026. It also disclosed FDA clearance for a Phase 1b study of TBS-2025 and preliminary major objective partial responses in the first 3 patients treated with IFx-2.0 alongside Keytruda®, ongoing for more than six months.
- Cash and cash equivalents totaled $1.9 million at September 30, 2026.
- Research and development expenses were $3.7 million, compared with $5.0 million for the prior-year quarter.
- The Parkview loan facility contributed $5.6 million in financing during the quarter ended September 30, 2026.
- FDA cleared a Phase 1b study of TBS-2025 in relapsed/refractory mut NPM1 acute myeloid leukemia.
earningsregulatoryfinancing
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | hura-20261113.htm |
| EX-99.1 | EX-99.1 | hura-ex99_1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.